Locoregional effects of pegylated liposomal doxorubicin (Caelyx) in irradiated area: a phase I-II study in patients with recurrent squamous cell carcinoma of the head and neck.

@article{Faivre2004LocoregionalEO,
  title={Locoregional effects of pegylated liposomal doxorubicin (Caelyx) in irradiated area: a phase I-II study in patients with recurrent squamous cell carcinoma of the head and neck.},
  author={Sandrine J. Faivre and Hassan Alsabe and Latifa Djafari and François Janot and Morbize Juli{\'e}ron and Christian Domenge and Kamel Djazouli and J. S. Armand and Bernard Luboinski and E Coen Raymond},
  journal={European journal of cancer},
  year={2004},
  volume={40 10},
  pages={
          1517-21
        }
}
Aim of this study was to determine the antitumour activity and toxicity of pegylated liposomal doxorubicin (Caelyx) in pretreated patients with locally recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). Caelyx was administrated as 1 h infusion every 3 weeks at doses of 35 mg/m2 (group A) and then subsequently given at 45 mg/m2 (group B). 26 patients received a total of 87 cycles. The median number of cycles was 3 (range 1-7). Four out of 24 evaluable patients (17… CONTINUE READING
BETA